共 40 条
Serum visfatin as a metabolic biomarker in obese patients with gestational diabetes mellitus
被引:9
作者:
Radzicka-mularczyk, Sandra
[1
]
Zaborowski, Mikolaj P.
[2
]
Brazert, Jacek
[1
]
Pietryga, Marek
[1
]
机构:
[1] Poznan Univ Med Sci, Dept Gynecol Obstet & Gynecol Oncol, Div Obstet & Womens Dis, Polna St 33, PL-60535 Poznan, Poland
[2] Poznan Univ Med Sci, Dept Gynecol Obstet & Gynecol Oncol, Div Gynecol Oncol, Poznan, Poland
来源:
MINERVA ENDOCRINOLOGY
|
2021年
/
46卷
/
04期
关键词:
Nicotinamide phosphoribosyltransferase;
Obesity;
Body Mass Index;
Diabetes;
Gestational;
Adipocyto-kines;
Pregnancy;
Glucose intolerance;
MESSENGER-RNA EXPRESSION;
PREGNANT-WOMEN;
GLUCOSE;
FAT;
HYPERGLYCEMIA;
TISSUE;
LEVEL;
D O I:
10.23736/S2724-6507.20.03280-0
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
BACKGROUND: Visfatin is an adipokine produced and secreted by the adipose tissue. It exerts an insulin-like effect by the insulin receptor-1 and has a hypoglycemic effect. We aimed to investigate how serum visfatin changes in women with gestational diabetes mellitus (GDM), and whether it is predictive of neonatal outcomes. METHODS: Visfatin levels were prospectively measured in peripheral blood serum by enzyme immunoassay in 210 pregnant women, 156 of which were diagnosed with GDM, 18 of which suffered from pregnancy-induced hypertension (PIH) and 36 healthy controls. RESULTS: Patients with obesity class II (median=2.562 ng/mL) and class III (median=6.2940 ng/mL) had higher serum visfatin than overweight patients (median=0.735 ng/mL); (Mann-Whitney U test, P=0.037 and P=0.023, respectively). In GDM patients with BMI above 30, serum visfatin was associated to glycosylated hemoglobin (Spearman correlation test, R=0.26, P=0.045). Women with BMI above 25 treated with insulin had lower serum visfatin levels than those treated with diet only (Mann-Whitney U test, P=0.045). No correlation was found between visfatin and parameters of lipid profile such as HDL, LDL, or triglycerides (Spearman correlation tests, R=-0.051,-0.1, 0.0019; P=0.54, 0.29, 0.98, respectively). We observed that visfatin was not associated with birth weight (Spearman correlation test, R=-0.014, P=0.86) or adverse neonatal outcome as measured by umbilical artery pH below 7.25 (Mann-Whitney U test, P=0.55) or Apgar score below 10 (Mann-Whitney U test, P=0.21). CONCLUSIONS: In GDM patients with higher BMI, serum visfatin was elevated, correlated positively with glycosylated hemoglobin, and decreased upon treatment with insulin therapy. (Cite this article as: Radzicka-Mularczyk S, Zaborowski MP, Brazert J, Pietryga M. Serum visfatin as a metabolic biomarker in obese patients with gestational diabetes mellitus. Minerva Endocrinol 2021;46:396-405. DOI:10.23736/S27246507.20.03280-0)
引用
收藏
页码:396 / 405
页数:10
相关论文